Literature DB >> 19078975

The biology of Hodgkin's lymphoma.

Ralf Küppers1.   

Abstract

Hodgkin's lymphoma was first described in 1832. The aetiology of this lymphoma, however, remained enigmatic for a long time. Only within the past 10 years has the B-cell nature of the pathognomonic Hodgkin and Reed-Sternberg (HRS) cells been revealed, along with several recurrent genetic lesions. The pathogenetic role for Epstein-Barr virus infection has also been substantiated. HRS cells in classical Hodgkin's lymphoma have several characteristics that are unusual for lymphoid tumour cells, and the Hodgkin's lymphoma microenvironment is dominated by an extensive mixed, potentially inflammatory cellular infiltrate. Understanding the contribution of all of these changes to the pathogenesis of this disease is essential for the development of novel therapies.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19078975     DOI： 10.1038/nrc2542

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  159 in total

1.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.

Authors:  R G Caldwell; J B Wilson; S J Anderson; R Longnecker
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

2.  On some Morbid Appearances of the Absorbent Glands and Spleen.

Authors: 
Journal:  Med Chir Trans       Date:  1832

Review 3.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  STAT3 is constitutively activated in Hodgkin cell lines.

Authors:  D Kube; U Holtick; M Vockerodt; T Ahmadi; B Haier; I Behrmann; P C Heinrich; V Diehl; H Tesch
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

5.  Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma.

Authors:  Axel Greiner; Stephanie Tobollik; Maike Buettner; Berit Jungnickel; Kathrin Herrmann; Elisabeth Kremmer; Gerald Niedobitek
Journal:  J Pathol       Date:  2005-04       Impact factor: 7.996

6.  Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

Authors:  P Fiumara; V Snell; Y Li; A Mukhopadhyay; M Younes; A M Gillenwater; F Cabanillas; B B Aggarwal; A Younes
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

Review 7.  Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma.

Authors:  Andreas Bräuninger; Roland Schmitz; Dörte Bechtel; Christoph Renné; Martin-Leo Hansmann; Ralf Küppers
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

8.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.

Authors:  Franziska Jundt; Ioannis Anagnostopoulos; Reinhold Förster; Stephan Mathas; Harald Stein; Bernd Dörken
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 9.  Cancer stem cells: at the headwaters of tumor development.

Authors:  Ryan J Ward; Peter B Dirks
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

10.  Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma.

Authors:  Toni Portis; Patricia Dyck; Richard Longnecker
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113
View more
  216 in total

Review 1.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

2.  Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Małgorzata Syczewska; Jan Walewski; Janina Kaminska
Journal:  Tumour Biol       Date:  2012-06-08

3.  Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.

Authors:  Björn Lamprecht; Korden Walter; Stephan Kreher; Raman Kumar; Michael Hummel; Dido Lenze; Karl Köchert; Mohamed Amine Bouhlel; Julia Richter; Eric Soler; Ralph Stadhouders; Korinna Jöhrens; Kathrin D Wurster; David F Callen; Michael F Harte; Maciej Giefing; Rachael Barlow; Harald Stein; Ioannis Anagnostopoulos; Martin Janz; Peter N Cockerill; Reiner Siebert; Bernd Dörken; Constanze Bonifer; Stephan Mathas
Journal:  Nat Med       Date:  2010-05-02       Impact factor: 53.440

4.  Hematology. Are macrophages the bad guys in Hodgkin lymphoma?

Authors:  Volker Diehl
Journal:  Nat Rev Clin Oncol       Date:  2010-06       Impact factor: 66.675

5.  KLHDC8B in Hodgkin lymphoma and possibly twinning.

Authors:  Andrew E Timms; Marshall S Horwitz
Journal:  Commun Integr Biol       Date:  2010-03

6.  Bone marrow stromal cells induced activation of nuclear factor κB signaling protects non-Hodgkin's B lymphoma cells from apoptosis.

Authors:  Tuo Su; Jiakai Li; Mingming Meng; Sheng Zhao; Yali Xu; Xinmin Ding; Hong Jiang; Xiaorong Ma; Jin Qian; Wei Han; Lixin Sun; Xiaobin Li; Zuojun Liu; Lei Pan; Xinying Xue
Journal:  Tumour Biol       Date:  2016-02-12

Review 7.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

8.  TSPAN33 is a novel marker of activated and malignant B cells.

Authors:  Van Phi Luu; Peter Hevezi; Felipe Vences-Catalan; José Luis Maravillas-Montero; Clayton Alexander White; Paolo Casali; Luis Llorente; Juan Jakez-Ocampo; Guadalupe Lima; Natalia Vilches-Cisneros; Juan Pablo Flores-Gutiérrez; Leopoldo Santos-Argumedo; Albert Zlotnik
Journal:  Clin Immunol       Date:  2013-08-15       Impact factor: 3.969

9.  Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Authors:  Stephanie Sasse; Katharina Reddemann; Arjan Diepstra; Ilske Oschlies; Antje Schnitter; Sven Borchmann; Andreas Engert; Peter Borchmann; Wolfram Klapper
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

10.  Disruption of direct 3D telomere-TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed-Sternberg cells.

Authors:  Hans Knecht; Nathalie A Johnson; Tina Haliotis; Daniel Lichtensztejn; Sabine Mai
Journal:  Lab Invest       Date:  2017-04-24       Impact factor: 5.662
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.